Suchergebnisse - "Nappi, Anna"

PubPharm (4)

1

Exploratory findings from a prematurely closed international, multicentre, academic trial : RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer

enthalten in: ESMO open | 2019

von Cardone, C. | Martinelli, E. | Troiani, T. | +15

2

Adherence and safety of regorafenib for patients with metastatic colorectal cancer : observational real-life study

enthalten in: Future oncology (London, England) | 2017

von Del Prete, S. | Cennamo, G. | Leo, L. | +10

3

Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment

enthalten in: ESMO open | 2017

von Martinelli, E. | Sforza, V. | Cardone, C. | +16

CommentIn: ESMO Open. 2017 Jul 29;2(3):e000205. - PMID 29303156

4

Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells

enthalten in: International journal of cancer | 2013

von Martinelli, E. | Troiani, T. | D'Aiuto, E. | +15

1
[1]